

January 31, 2017
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

**Japan Launch of the Anti-cancer Drug
TREAKISYM® Intravenous Infusion 25 mg**

TOKYO, Japan, January 31, 2017 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") announced today the launch in Japan of TREAKISYM® Intravenous Infusion 25 mg, a standard low-dose product (non-proprietary name: bendamustine hydrochloride), through SymBio's commercialization partner, Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") for the treatment of low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma, and chronic lymphocytic leukemia. TREAKISYM® Intravenous Infusion 25 mg was approved for manufacturing and marketing in Japan on September 28, 2016, and was added to Japan's National Health Insurance drug price list on November 18, 2016.

Eisai is exclusively in charge of marketing TREAKISYM® Intravenous Infusion 25 mg in accordance with the license agreement between SymBio and Eisai.

In an effort to address unmet medical needs, SymBio will pursue the proper use of TREAKISYM® and maximize its product value.

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125

About Non-Hodgkin's Lymphoma

This is a group of blood cancers that includes all types of lymphoma except Hodgkin's lymphoma, where certain cells of the lymph system become cancerous. Non-Hodgkin's lymphoma accounts for the majority of lymphomas in Japan. Non-Hodgkin's lymphoma is categorized by progression speed; Lymphoma progressing in years is classified as low-grade, and in months or weeks as intermediate to high-grade. SymBio estimates that the total number of patients in Japan with low-grade non-Hodgkin's lymphoma is around 11,800.

About TREAKISYM®

From first use in Germany in the 1970s, TREAKISYM®, a cytocide anti-cancer drug, is now widely used in more than 50 countries with indications for low-grade B-cell non-Hodgkin's lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia.

- TREAKISYM® Intravenous Infusion 100 mg was approved in Japan in October 2010 for manufacturing and marketing for the indication of recurrent/refractory low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma, and has been marketed through Eisai Co., Ltd. since December 2010.
- TREAKISYM® Intravenous Infusion 100 mg was approved for the additional indication of chronic lymphocytic leukemia in Japan in August 2016.
- TREAKISYM® Intravenous Infusion 25 mg, a standard low-dose product, was approved for manufacturing and marketing in Japan in September 2016.
- TREAKISYM® was approved for the additional indication of first-line treatment of low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma in Japan in December 2016.

<Product Description>

- Product name: TREAKISYM® for Intravenous Infusion 100 mg, 25 mg
- Generic name: bendamustine hydrochloride
- Indications and usage:
 1. Low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma
 2. Chronic lymphocytic leukemia
- Dosage and administration:
 1. Low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma

(1) Untreated (first-line treatment)

In combination with rituximab (genetic recombination), the recommended adult dose is bendamustine hydrochloride 90 mg/m² (body surface area) via 1-hour intravenous infusion once daily for 2 days on treatment, followed by 26 days off treatment, with repeated cycles. Dosage may be reduced as appropriate in accordance with the patient's condition.

(2) Relapsed or refractory forms

The recommended adult dose is bendamustine hydrochloride 120 mg/m² (body surface area) via 1-hour intravenous infusion once daily for 2 days on treatment, followed by 19 days off treatment, with repeated cycles. Dosage may be reduced as appropriate in accordance with the patient's condition.

2. Chronic lymphocytic leukemia

The recommended adult dose is bendamustine hydrochloride 100 mg/m² (body surface area) via 1-hour intravenous infusion once daily for 2 days on treatment, followed by 26 days off treatment, with repeated cycles. Dosage may be reduced as appropriate in accordance with the patient's condition.

- Listed price: TREAKISYM® for Intravenous Infusion 100 mg: Yen 94,995/vial
 TREAKISYM® for Intravenous Infusion 25 mg: Yen 29,295/vial

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the U.S., called SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.